Literature DB >> 16670274

Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma.

Murali Gururajan1, C Darrell Jennings, Subbarao Bondada.   

Abstract

B lymphomas account for the majority of the lymphoma cases. BCR expression appears to be important for B lymphoma because most oncogenes are translocated to nonrearranged Ig loci and because all of the variants that arise in anti-idiotypic Ab-treated lymphoma patients remain BCR positive. Based on this and the fact that BCR is required for mature B cell survival, we tested the requirement for continued expression of BCR for the growth and survival of B lymphoma cells. Using Igalpha or Igbeta-specific small interfering RNA (siRNA) to inhibit BCR expression, we demonstrate for the first time that constitutive signaling by BCR is critical for survival and proliferation of both murine and human B lymphoma cells. The BCR signals in lymphoma appear to be mediated by Syk, as it is constitutively active in a variety of B lymphoma cells. Blocking Syk activity by selective inhibitors suppresses growth of several murine and human B lymphomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16670274     DOI: 10.4049/jimmunol.176.10.5715

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.

Authors:  Vaishalee P Kenkre; Brad S Kahl
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

Review 2.  Pathogenesis of diffuse large B cell lymphoma.

Authors:  Wing John C Chan
Journal:  Int J Hematol       Date:  2010-06-29       Impact factor: 2.490

3.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

4.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

Authors:  Jan A Burger; Maite P Quiroga; Elena Hartmann; Andrea Bürkle; William G Wierda; Michael J Keating; Andreas Rosenwald
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

5.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.

Authors:  Chih-Hang Anthony Tang; Sujeewa Ranatunga; Crystina L Kriss; Christopher L Cubitt; Jianguo Tao; Javier A Pinilla-Ibarz; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

7.  The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Authors:  Stephen E Spurgeon; Greg Coffey; Luke B Fletcher; Russell Burke; Jeffrey W Tyner; Brian J Druker; Andreas Betz; Francis DeGuzman; Yvonne Pak; Dale Baker; Anjali Pandey; Stanley J Hollenbach; Uma Sinha; Marc M Loriaux
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

8.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

9.  Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study.

Authors:  Hekmat Osman Abdel-Aziz; Yoshihiro Murai; Ichiro Takasaki; Yoshiaki Tabuchi; Hua-chuan Zheng; Kazuhiro Nomoto; Hiroyuki Takahashi; Koichi Tsuneyama; Ichiro Kato; Daniel K Hsu; Fu-tong Liu; Koichi Hiraga; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

10.  Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.

Authors:  Jiyuan Ke; R Lakshman Chelvarajan; Vishal Sindhava; Darrell A Robertson; Lazaros Lekakis; C Darrell Jennings; Subbarao Bondada
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.